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THE EFFECTIVENESS OF HS-72 VARIANTS IN INHIBITION OF HEAT 
SHOCK PROTEIN 72 
KATHERINE FRAILE 
ABSTRACT 
 Heat shock proteins (HSPs) play important roles in the process of maintaining 
proteostasis in a cell. HSP72, the inducible form of the HSP70 family, is expressed in 
response to stress on the cell or tissue, including those stresses caused by tumor growth. 
Increasing evidence suggests that HSP72 is necessary for a cancerous cell to survive 
under the stresses of a tumor microenvironment. This has naturally raised interest in 
identifying an inhibitor selective for HSP72. The Haystead Laboratory at Duke 
University identified such a small-molecule inhibitor, referred to as HS-72, and proposed 
the scaffold as an ideal starting point to develop a family of therapeutic agents targeting 
HSP72. 
 This work examines the potency and effectiveness of HS-72 and a number of its 
analogs developed by the Haystead Laboratory. These results suggest that HS-159 is a 
more effective inhibitor of HSP72 on a range of human tumor cell lines than HS-72. 
Further studies are needed to quantify how much more potent HS-159 is than HS-72 and 
potentially identify even more potent compounds. 
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INTRODUCTION 	  
 In recent years, the scientific community has grown very interested in the role of 
heat shock proteins (HSP) in cancer and their potential as therapeutic targets. The 72 kDa 
heat shock protein, HSP72, has drawn specific interest because of its inducible nature and 
overexpression in the cancer phenotype. This study seeks to characterize the anticancer 
activity of a series of small molecule inhibitors of HSP72 that were identified at Duke. 
Heat Shock Proteins 
 Heat shock proteins were first discovered in 1962 and were originally defined in 
the context of their increased expression following exposure to heat, heavy metals, and 
oxidative stress (Lianos et al., 2015; Powers & Workman, 2007). They are grouped into 
families by size and function: HSP90, HSP70, HSP60, and small HSPs (Jego, Hazoumé, 
Seigneuric, & Garrido, 2013; Lianos et al., 2015; Powers & Workman, 2007). HSPs are 
highly evolutionarily conserved across species (Howe et al., 2014; Jego et al., 2013). 
Most HSPs regulate essential functions within cells. For example, they serve as molecular 
chaperones, protecting client proteins from proteolysis. They are involved in the 
assembly and maintenance of protein complexes, and intracellular protein trafficking and 
secretion. Heat shock proteins have also been shown to regulate transcription factors 
(Lianos et al., 2015).   
 Induction of HSPs is a key component of the heat shock or stress response (HSR), 
which is characterized by a series of biochemical and molecular events that protect cells 
from initial and repeat exposure to proteotoxic stress or injury (Powers & Workman, 
2007). Indeed, HSPs are thought to be necessary for cell survival under stress 
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(Calderwood, Khaleque, Sawyer, & Ciocca, 2006). The cytoprotective effects include 
anti-apoptotic mechanisms by which HSPs bind to and inactivate key players in the 
apoptotic machinery (Jego et al., 2013). 
 The HSP70 family is of specific interest in cancer biology. This family is highly 
conserved and consists of HSPs between 66kDa-78kDa (Powers & Workman, 2007). 
There are eight mammalian HSPs in this family (Howe et al., 2014). All members have 
similar structures in their N-terminal ATPase and substrate-binding domains. The 
~10kDa C-terminal domain is the most variable and contains the EEVD motif in most 
isoforms; this is the site where co-chaperones interact. HSP70 family members protect 
against programmed cell death at different points along the apoptotic pathway. HSP70 
can prevent the loss of mitochondrial membrane potential upon exposure to apoptotic 
stimuli, blocking apoptogenic factor release (e.g. cytochrome c or AIF). Alternatively, 
HSP70 can act downstream of the mitochondria, directly inhibiting APAF-1 or AIF. 
HSP70 also potently inhibits caspase-independent death by modulating the pro-apoptotic 
JNK pathway (Powers & Workman, 2007). 
 The HSP70 family includes both the highly stress-inducible HSP72 (HSP70i, 
HSPA1, HSP70-1) and the constitutively expressed Hsc70 (HSP73, HSPA8). Under 
normal conditions, HSP70s are ATP-dependent, requiring ATP hydrolysis in the N-
terminal NBD (nucleotide binding domain) (Howe et al., 2014; Jego et al., 2013). We are 
particularly interested in the actions of HSP72, which we will consider later.  
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Heat Shock Proteins and Cancer 
 Recent evidence shows that protein levels of HSPs are elevated in the cancer 
phenotype. This suggests that cancer cells are more dependent on HSPs, perhaps because 
of the hostile conditions created by deregulated oncogenes or the stress of the solid tumor 
microenvironment, which includes nutrient starvation, hypoxia, and acidosis (Powers & 
Workman, 2007). HSP levels are increased in most stages of tumor development and in 
the process of developing drug resistance. When non-malignant cell undergo oncogenic 
transformation, HSPs protect newly transformed cells from undergoing oncogene induced 
senescence (OIS), instead, enabling them to grow and survive (Calderwood et al., 2006). 
In addition, cytotoxic chemotherapies can induce HSP expression in tumor cells, which 
may play a role in the development of therapeutic resistance. Moreover, studies have 
shown that increased HSP levels in tumors are associated with poor clinical outcomes 
(Jego et al., 2013). 
 In mouse models, overexpression of HSP70 resulted in increased tumor growth, 
metastatic dissemination and resistance to treatment with chemotherapeutic agents. 
Conversely, depletion or inhibition of HSP70 resulted in decreased tumor size (Jego et 
al., 2013). Akerfelt et al. showed that mice lacking HSF1, the transcription factor that 
regulates HSP expression, have lower tumor incidence and better survival in a classical 
chemical skin carcinogenesis model as well as in a model with an oncogenic mutation of 
p53. They found similar results with human cancer cell lines with HSF1 depleted by 
RNAi strategies (Åkerfelt, Morimoto, & Sistonen, 2010). 
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HSP72 
 HSP72 is of particular interest as a target for therapeutic treatment. In unstressed 
non-malignant cells, HSP72 is expressed at low or undetectable levels. Upon exposure to 
proteotoxic stress, HSP72 protein expression increases (Howe et al., 2014; Volloch & 
Sherman, 1999). When the stress is removed, levels decrease to baseline as HSP72 is 
degraded, or aggregates into granules where it is then permanently inactivated (Volloch 
& Sherman, 1999). The inducing stress is not limited to heat shock, but can also include 
viral infection, transformation, and various forms of cancer (Howe et al., 2014).  
 High levels of HSP72 protein are expressed in tumors, and overexpression 
correlates with a highly aggressive phenotype including increased invasiveness and  
metastatic dissemination, chemo-resistance, and poor clinical outcome (Howe et al., 
2014; Jego et al., 2013; Lianos et al., 2015; Volloch & Sherman, 1999; Yaglom, Gabai, & 
Sherman, 2007). HSP72 can protect cancer cells from stress by providing another route to 
survive in the inhospitable tumor microenvironment e.g. hypoxia, or in the presence of 
denatured protein aggregates caused by chemotherapy and radiation (Howe et al., 2014). 
Indeed, it seems that constitutively high HSP72 expression is essential for cancer cell 
survival. Down-regulating HSP72 has a significantly stronger effect in transformed cell 
lines than in primary cell lines, indicating that tumor cells seem to constitute a stressed 
phenotype and are more dependent on the cytoprotective effects of HSP72 (Jego et al., 
2013). When HSP72 is depleted in tumorigenic and non-tumorigenic cell lines, the 
tumorigenic cells show significantly increased sensitivity to the killing effects of 
cytotoxic agents, whereas the non-tumorigenic lines are unaffected (Howe et al., 2014). 
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 Volloch et al. sought to understand the mechanism underlying the association 
between HSP72 overexpression and oncogenic transformation. It was believed that 
oncogenic transformation induces HSP72 expression, but could the converse be true? 
They tested the question in mice and found that sustained elevated levels of HSP72 result 
in oncogenic transformation in immortalized cells. It is noteworthy to mention that aged 
mammalian cells show a decreased ability to express HSP72 in response to stress. 
Without this phenomena, as cells faced the stress of aging, HSP72 would be 
constitutively expressed and greatly increase the likelihood of cancer occurrence as 
people age (Volloch & Sherman, 1999). 
 HSP72 has a key role in cancer initiation and progression because it helps cells 
avoid the apoptosis that would otherwise be caused by tumor microenvironment stress 
and by anti-cancer drugs. HSP72 can inhibit apoptosis at many points, through both the 
intrinsic and extrinsic apoptotic pathways (Lianos et al., 2015). HSP72 inhibits events in 
mitochondrial-mediated apoptosis by blocking Bax translocation to the mitochondria, 
which in turn blocks cytochrome C release and prevents apoptosis. HSP72 also inhibits 
death receptors 4 and 5, preventing TNF-related ligand formation of the death-induced 
signaling complex that promotes apoptosis. HSP72 also mediates caspase dependent and 
independent apoptosis by binding Apaf-1 and thus blocking procaspase-9 recruitment to 
the apoptosome in the caspase-dependent pathway, and by JNK inhibition in the caspase-
independent pathway (Calderwood et al., 2006; Howe et al., 2014). Cells that evade 
apoptosis through these mechanisms can still undergo necrosis. Moderate levels of 
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necrosis lead to inflammation and angiogenesis, which promotes tumor cell invasion and 
metastasis (Calderwood et al., 2006). 
 Cell proliferation can also be limited by terminal cell senescence. Targeted siRNA 
mediated depletion of HSP72 in newly transformed human epithelial cell lines has been 
shown to trigger cell senescence via p53-dependent and independent pathways as 
evidenced by increased senescence associated β –galactosidase activity (Calderwood et 
al., 2006; Lianos et al., 2015; Yaglom et al., 2007). Decreased HSP72 can also inactivate 
the cell cycle kinase, Cdc2, causing G2-M cell cycle arrest and cell senescence (Yaglom 
et al., 2007). 
Challenges of Developing a Therapeutic Agent and Previous Attempts 
 While there is good rationale to develop an agent to inhibit HSP72 as a 
therapeutic treatment for cancer, the process has proved difficult. One of the most 
difficult challenges is that HSP72 shares 90% of its sequence with the constitutively 
active Hsc70, inhibition of which would be lethal. The only known phenotype of the 
HSP72 knockout mice is reduced sperm count in male mice. Other challenges to 
identifying an HSP72 inhibitor include its poorly defined physiological substrates and the 
fact that its nuclear binding pocket is always occupied by ATP or ADP, limiting small 
molecule accessibility. Past inhibitors have failed to discriminate between members of 
the HSP70 family or have performed poorly in vivo (Howe et al., 2014).  
 Quercetin, a naturally occurring flavonoid, has been found to inhibit HSP 
expression by modulating HSF1 activity and thus inhibiting cancer cell growth both in 
vitro and in vivo. This inhibitor is selective to tumor cells compared with non-malignant, 
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cells; however, it is not specific as it has promiscuous inhibitory effects on many protein 
kinases. KNK437, a lactam, is another inhibitor that showed early promise. Both of these 
drugs, however, are not ideal for clinical use because of their low potency; they require 
high concentrations on the order of 100-500 µM to be effective. The specificity of the 
inhibitors has to be questioned at these high concentrations (Powers & Workman, 2007). 
 Jego et al. showed that ADD70 (AIF derived decoy for HSP70), an HSP70 
inhibitor, reduced the size of established tumor xenografts and led to tumor growth delay 
in mice. ADD70 also sensitized the mice to cisplatin, a DNA alkylating agent used to 
treat a variety of solid tumors. Notably, ADD70 is specific to HSP72 but not 
constitutively active Hsc70. These effects were not observed in immunodeficient animals. 
The mechanism of ADD70 antitumor activity has been attributed to a CD8+ T-cell 
immune response (Jego et al., 2013; Powers & Workman, 2007). Recent investigation has 
also identified PES (2-phenylethynesulfonamide) as a small molecule inhibitor for 
HSP70. PES causes protein aggregation leading to autophagy or caspase-dependent 
apoptosis. Both ADD70 and PES target the peptide binding domain (Jego et al., 2013). 
 It is widely recognized that inhibition of HSP90 in vitro and in vivo results in 
upregulation of HSP72. This effect is demonstrated by studies using siRNA mediated 
depletion of HSP72, which results in increased sensitivity of leukemia cell lines to the 
antitumor activity of HSP90 small molecule inhibitors (Powers & Workman, 2007). 
17AAG, an HSP90 inhibitor that showed clinical efficacy in Phase I and II trials, is 
selective for tumor cells but may also lead to resistance to cancer therapy because HSP90 
is no longer able to buffer against altered phenotype cancer cells (Calderwood et al., 
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2006). Naturally, it will be desirable to combine HSR modulators to evaluate the 
potential synergistic effect of HSP90 and HSP72 inhibitors together. 
 
Identification of HS-72 and Its Analogs 
 In a recent publication from the Haystead Laboratory at Duke University, Howe 
et al. were able to identify an allosteric small molecule inhibitor that selectively binds to 
HSP72. They identified the compound by using fluorescence-linked enzyme 
chemoproteomic strategy (FLECS) on a chemical screen of their in-house library of 
3,379 purine-like molecules. Notably this inhibitor is selective over Hsc70. HS-72 is an 
allosteric inhibitor thought to bind at the NBD of HSP72 (Figure 1). It is hypothesized 
that HS-72 binds HSP72 causing a conformational change that alters the surface exposure 
to trypsin, protecting certain sequences from trypsin degradation. In murine studies, HS-
72 appears to be well-tolerated, bioavailable, and reduced tumor growth in the MMTV-
neu breast cancer model (Howe et al., 2014). 
 
	  9 
 
Figure 1: Molecular Modeling Supports HS-72 as an Allosteric Inhibitor of HSP72. 
These models show two different views of the HSP72 NBD and highlight two potential 
binding sites of HS-72 (Figure adapted from Howe et al., 2014). 
 For the above reasons, HS-72 is considered an ideal starting point for further 
chemical modification to improve potency. The initial isolate was racemic, so a separate 
R confirmation (now known as HS-71) and the more effective S confirmation (HS-72) 
were resynthesized (Howe et al., 2014). The Haystead Laboratory next developed 
nineteen analogs of HS-72 with structures shown in Figure 2. We sought to test which of 
these analogs exhibit increased potency compared with HS-72.  
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Figure 2: HS-72 Analog Structures. Chemical structures of the resynthesized analogs of 
HS-72 (Figure supplied by the Haystead Laboratory). 
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Specific Objectives 
 In order to identify an analog more potent than HS-72 we will: 
 (1) Assess the effect of each compound on cell viability at a range of 
concentrations using an ATP concentration luminescence assay. 
 (2) Evaluate the consistency of a promising compound(s) on the viability of 
different human tumor and non-malignant cell lines. 
 (3) Determine the effects of a more potent compound(s) on cell cycle kinetics and 
viability. 
 (4) Assess the effect of HSP72 inhibitors on oncogene-induced senescence. 
 
 We expect these studies will show: 
 (1) There is at least one analog that is more potent than HS-72 at inhibiting 
HSP72 and inducing cell death.  
 (2) A more potent HSP72 inhibitor exerts its effects by inhibiting anti-apoptotic 
pathways resulting in increased cell death and an increased proportion of cells in early 
apoptosis. 
 (3) A more potent HSP72 inhibitor will trigger cell senescence, which will 
eventually lead to apoptosis. 
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METHODS 	  
Tissue Culture 
 The following human cell lines were used for these studies: (i) MCF10A, an 
immortalized, non-malignant breast epithelial cell line; (ii) MCF10A cells expressing the 
p110 oncogenic truncated form of HER2 under the control of doxycycline-inducible 
promoter; (iii) BT474 cells, a human invasive ductal breast carcinoma cell line; and (iv) 
T pancreatic tumor cells. These cell lines were maintained in log growth phase in tissue 
culture throughout the course of experiments. Transformed and untransformed MCF10A 
cells were each cultured separately with or without 0.25 µg/mL doxycycline. 
 MCF10A cells were cultured in 500mL DMEM/F12 base medium supplemented 
with 25mL heat inactivated horse serum, 100µL EGF (100 mg/mL), 250µL 
hydrocortisone (1mg/mL), 50µL choleraToxin (1mg/mL), 500µL insulin (10mg/mL) and 
5.0mL pen/strep. BT474 cells were cultured in RPMI 1640 medium supplemented with 
10% heat inactivated fetal bovine serum. DT cells were cultured in DMEM/M3:BaseF 
(Incell Corporation) base medium supplemented with 10% heat inactivated fetal bovine 
serum. 
ATP Concentration Luminescence Assay 
  To identify the most promising HSP72 inhibitor, each of the analogs was tested at 
a range of concentrations in BT474 cells, and ATP concentrations were measured to 
determine the concentration of remaining viable cells. BT474 cells were plated at 3 x 103 
cells per well on 96-well plates. Medium was replaced and individual compounds were 
added 24 hours later at the following concentrations (µM): 0, 4.5, 6, 9, 12, 18, 25, 38, 50, 
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and 75. After 72 hours, the medium was removed and Promega Luciferase Reagent was 
added, and after 10 minutes the plates were read. The luminescence was measured using 
a GENios Luminescence Microplate Reader. 
 This process was later repeated using HS-72, HS-157, HS-159, and HS-160 in 
BT474, DT, MCF10A p110 -Dox, and MCF10A p110 +Dox cell lines. 
β -Galactosidase Activity for Senescence 
  Western blot analysis was used to test for senescence associated β-galactosidase 
activity. MCF10A, MCF10A p110 -Dox, and MF10A p110 +Dox cells were plated at 1.4 
x 104 cells per well under the following treatment conditions for each compound: no 
compound, 40 µM 0.01% DMSO, 10 µM HS-72, 20 µM HS-72, 30 µM HS-72, 40 µM 
HS-72, 5 µM HS-159, 10 µM HS-159, 15 µM HS-159, 20 µM HS-159, 30 µM HS-159, 
and 40 µM HS-160. The cells were maintained for two weeks and then protein extracts 
were collected for Western blot analysis. 
 To collect for Western blot analysis, the cells were collected in trypsin, washed 
several times in PBS and centrifuged, and the pellet was re-suspended in RIPA lysis 
buffer. After another 10 minute centrifuge, the supernatant was collected and added to a 
loading buffer. The samples were then loaded onto Biorad Mini-PROTEAN TGX. 
Vertical gel electrophoresis was run with the Biorad Mini-PROTEAN tetra cell, and the 
gel was then transferred to a membrane with a Thermofisher iBlot Gel Transfer Device.  
 The membranes were blocked in a solution of 5% dry milk in PBS-T for an hour. 
The membranes were soaked in a solution of 1% dry milk in PBS-T with the following 
Santa Cruz primary antibodies overnight: α- β-galactosidase (Mouse) at 1:500, α-actin 
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(Mouse) at 1:2000, and α-HSP70 (Rat) at 1:2000. The next day, the membranes were 
washed in PBS-T for one hour, with fresh PBS-T every 15 minutes. Then they were 
soaked in a solution of 1% dry milk in PBS-T with the following Santa Cruz secondary 
antibodies for one hour: 800-labeled anti-mouse antibody at 1:10,000 and 670-labeled 
anti-rat antibody at 1:10,000. The membranes were once again washed with PBS-T for 
one hour with 15 minute PBS-T changes. They were then rinsed with water and scanned 
on the Odyssey Infrared Imaging System. 
Flow Cytometry 
  BT474 cells were plated at 4.2 x 104 cells per well on a 12-well plate. After 24 
hours, the medium was replaced and compounds were added. Three wells were treated 
with HS-72 at 15 µM, 40 µM, and 50 µM. Three wells were treated with HS-159 at 5 µM, 
10 µM, and 20 µM. Three wells were treated with HS-160 at 50 µM each, and three wells 
were treated with no compound. The cells were grown in compound for 72 hours. At this 
point the cells were dissociated with trypsin and collected. The samples were sent to 
Duke University’s Flow Cytometry Shared Resource facility for flow cytometric analysis 
with Annexin V and 7AAD markers to mark for early apoptosis and cell death, 
respectively. 
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RESULTS 
 
 
ATP Concentration Luminescence Assay on Each Analog 
 A dose-response curve was plotted for each compound where the average 
luminescence at each concentration of compound, representative of cell viability, was 
compared to the no compound treatment control. The data was fit with a third degree 
polynomial line of best fit and the concentration at which 50% of cells are predicted to be 
dead, an approximated LD50 was determined for each compound. Those values are shown 
in Table 1. The original graphs for each compound are provided in Appendix A. HS-159 
shows the lowest LD50 at 10.88 µM. HS-157 and HS-197 were less potent with LD50 
values of 16.24 µM and 18.01 µM, respectively. The averaged LD50 of HS-72 across four 
independent experiments was 18.53 µM.  
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Table 1. LD50 Values of Compound Analogs 
The concentration curves were fit with a third degree polynomial curve. The 
concentration at which the percent of luminescence compared to the non-compound 
control luminescence value was predicted to be 50% was calculated. If there were 
multiple plates for the same compound, those values were averaged to give the values 
below.  
*The third degree polynomial fit does not have a solution for y=50%. 
 
DRUG	   LD-­‐50	  (uM)	  
HS-­‐72	   18.53	  
HS-­‐197	   18.01	  
HS-­‐174	   59.31	  
HS-­‐173	   107.77	  
HS-­‐172	   N/A*	  
HS-­‐171	   84.48	  
HS-­‐170	   57.35	  
HS-­‐169	   N/A*	  
HS-­‐168	   61.05	  
HS-­‐163	   76.83	  
HS-­‐162	   77.18	  
HS-­‐161	   25.27	  
HS-­‐160	   N/A*	  
HS-­‐159	   10.88	  
HS-­‐158	   N/A*	  
HS-­‐157	   16.24	  
HS-­‐156	   59.09	  
HS-­‐155	   31.41	  
HS-­‐154	   N/A*	  
HS-­‐153	   N/A*	  
 
HS-159 ATP Concentration Luminescence Assay on Different Cell Lines 
 A dose-response curve was plotted for each compound on each of the four cell 
lines where the average luminescence at each concentration, representing a measure of 
cell viability, was compared to the no compound treatment control. As shown in Figure 3, 
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the effect of HS-159 was consistent on DT and BT474 cell lines as well as the MCF10A 
p110 cell line with and without doxycycline. 
	   	  
	   	  
 
Figure 3: Luminescence Graphs for HS-159 on Different Cell Lines. 
These graphs show the result of ATP luminescence measurements for the indicated cell 
lines treated with HS-159 for 72 hours. The y-axes represent % compared to the control, 
and the x-axes represent concentration in µM. (A) BT474 cells, (B) DT cells, (C) 
MCF10A p110 cells without doxycycline, (D) MCF10A p110 cells with 0.25 µg/mL 
doxycycline. 
 
HS-159 Flow Cytometry 
 Treating cells with HS-160 showed no appreciable difference to the control group. 
Compared to controls, treatment with HS-72 and HS-159 resulted in an increased number 
and proportion of cells in early apoptosis. There was a direct correlation between 
concentration of compound and induction of apoptosis. In side by side comparison at low 
concentrations of compound, HS-159 increased the proportion of early apoptotic cells 
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compared with HS-72. Specifically, when cells were treated with HS-72 at 30 µM, flow 
cytometry showed 68.53% of cells were viable and 18.18% were undergoing early 
apoptosis. At only 20 µM, 64.17% of cells treated with HS-159 were viable and 21.4% 
were undergoing early apoptosis. 
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Figure 4: Flow Cytometry Results of HS-159 and HS-72 on BT474 cells. 
The flow cytometry results on BT474 cells treated for three days with HS-72, HS-159 
and control conditions of no drug and the negative control HS-160 are shown above. (A) 
7AAD and Annexin V negative viable cells; (B) Annexin V positive/7AAD negative 
early apoptotic cells; (C) 7AAD positive/Annexin V negative dead cells; and (D) 
Annexin V and 7AAD positive apoptotic cells. 
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β –Galactosidase Staining 
 The results of staining for β –galactosidase activity were inconclusive. With cell 
densities clearly being variable after compound treatment for one or two weeks and no 
way to quantify the density of stained cells, we could not determine the effect that each 
drug treatment had on relative levels of senescence.  
β –Galactosidase Protein Western Blot Analysis 
 The Western blots were analyzed for the strength of signal, with the strength of 
each signal normalized to the strength of the actin signal for each sample. When the β –
galactosidase : actin ratio was normalized to the DMSO control for each cell condition, 
the experimental conditions, those samples treated with HS-72 and HS-159, showed a 
lower ratio of β –galactosidase, indicating lower relative levels of senescence than the 
control. This data is presented in Table 2 and Figure 5. 
 
Table 2: Western Blot Analysis Normalization for MCF10A p110. 
The tables show the intensity of signal for the antibody to each protein, the β−gal :actin 
normalization, and the normalization to the DMSO control. These results are from 
MCF10A-p110 cells treated with each compound for 2 weeks. Note that the 
concentration of HS-160 was 40 µM, HS-159 at 5 µM, and HS-72 at 10 µM. (A) Without 
doxycycline. (B) With 0.25 µg/mL doxycycline.  
 
 
A	   DMSO	   HS-­‐160	   HS-­‐159	   HS-­‐72	  β	  –galactosidase	  	   5100	   68400	   40900	   36300	  actin	   323000	   333000	   460000	   325000	  β	  –galactosidase	  :	  actin	   0.159	   0.205	   0.0889	   0.112	  
normalized	   1	   1.288	   0.558	   0.701	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B	   DMSO	   HS-­‐160	   HS-­‐159	   HS-­‐72	  β	  –galactosidase	  	   90500	   97600	   79000	   49300	  actin	   243000	   314000	   309000	   226000	  β	  –galactosidase	  :	  actin	   0.372	   0.311	   0.256	   0.218	  
normalized	   1	   0.835	   0.686	   0.586	  
 
 
Figure 5: Western Blot Analysis in MCF10A-p110 cells. 
MCF10A-p110 after 2 weeks of treatment with the indicated compounds. Note that HS-
160 was administered at 40 µM, HS-159 at 5 µM, and HS-72 at 10 µM. (A) Without 
doxycycline. (B) With 0.25 µg/mL doxycycline.  
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DISCUSSION 
 
 This study confirms the results of the Howe et al. study showing that HS-72 is an 
inhibitor of HSP72. It also demonstrates that HS-159 is a more potent inhibitor of HSP72 
with a measured LD50 of 10.88µM compared to 18.53µM. HS-157 and HS-197 proved to 
be effective inhibitors, but not significantly more potent than HS-72. We also showed 
that other analogs of HS-72 that were tested are either ineffective or less potent than HS-
72. These include HS-153, HS-154, HS-155, HS-156, HS-158, HS-160, HS-161, HS-162, 
HS-163, HS-168, HS-169, HS-170, HS-171, HS-172, HS-173, and HS-174.  
 Preliminary tests of HS-159 on various cell lines suggest that HS-159 is an 
effective and potent inhibitor on a range of cell lines and has clinical potential in breast 
and pancreatic cancers, as well as potentially other tumor types. Flow cytometry results 
showed that HS-159, to a greater degree than HS-72, caused early apoptosis. This 
confirms our hypothesis that HS-159 inhibition of HSP72 diminishes the anti-apoptotic 
effect of HSP72. 
 Our initial hypothesis was that HS-72 and HS-159 inhibit HSP72, which in turn 
increases cell senescence in response to oncogenic transformation, in this case the p110 
oncogenic form of HER2. However, Western blot protein analysis of cells treated with 
these compounds does not reveal an increase in senescence as measured by β –
galactosidase activity. We collected protein extracts for Western blot analysis after one 
and two weeks of treatment with HS-72 and HS-159. In light of these results, it is 
possible that HS-72 and HS-159 exert their antitumor effects through a pathway 
involving increased cell senescence, but by the time the cells were collected, they had 
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died. Further studies with Western blot analysis at earlier time periods are necessary to 
test this theory. 
 While the discovery of a more potent inhibitor than HS-72 is promising, it is 
noteworthy to mention that this study represents a very small sample size and HS-159 is 
less than twice as potent as HS-72. Ideally, another inhibitor can be developed or 
identified that is an order of magnitude more potent than HS-72. The modification from 
HS-72 to HS-159 involves increased branching of the side chain (Figure 2, see 
designation 4). Thus, further modification or addition of methyl groups to this side chain 
shows promise as a starting point for development of a more effective compound. 
 Further studies should also examine the effects of combining an HSP72 inhibitor 
such as HS-159 with an HSP90 inhibitor. We suggest that these two inhibitors may act 
synergistically and will have the greatest clinical potential when combined. 
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cognitive development of individuals with Duchenne 
Muscular Dystrophy. 
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1/11 – 4/11   University of Pittsburgh Freshmen Engineering Conference Paper 
Researched and presented an integrated approach to tissue 
engineering via mesenchymal stem cells, scaffolds, and 
bioreactors. 
 
Employment: 
  Appalachia Service Project 
 Appalachia Service Project is a non-profit organization 
seeking to eradicate substandard housing within the Central 
Appalachia region.  
5/12 – 8/12 Served as Volunteer Coordinator in Avery County, NC in 
2012. Worked on a team of four to manage 500+ teenage 
and adult volunteers; manage an $80,000+ budget; select, 
plan for, and manage 17 construction projects through 
seven weeks of volunteer-administered repairs; engage with 
community leaders and community contacts. Worked 
unconventional hours to very tight deadlines. 
5/14 – 8/14 Served as Staff Liaison assisting about 10 staff teams 
across TN, KY, VA, WV, and NC and liaising between the 
staffs and the non-profit’s administration. 
 
Leadership and Activities: 
9/11 – 5/14   Duke Division I Women’s Lacrosse Team 
Participated in 30+ hours per week practicing, training, 
competing, and reviewing film. Represented Duke 
Athletics by supervising and hosting prospective student-
athletes. 
7/11 – 5/14  Oncology Recreation Therapy Volunteer, Duke Hospital 
250+ total hours providing patients with interactive 
psychosocial therapy in order to develop, regain, or 
maintain the patients’ capacity for full living. Led the 
Living History Program, which involved developing 
relationship with patients and writing a powerful one-page 
story about his or her life in order to strengthen connections 
between the patient and the care delivery team. 
3/13 – 5/14  Duke Partnership for Service President 
Managed an executive board of 14 that supported and 
coordinated the 70+ student service groups at Duke, 
connected individual students to those groups and other 
service initiatives, led events and campaigns to inspire the 
campus to service. Collaborated with school administration 
and various partners across Duke and Durham. Oversaw a 
budget of $80,000. 
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8/13 – 5/14  Transfer Advisory Council Chair 
Serve as council Chair in 2013-2014 academic year 
managing 8 student counselors and coordinating all 
orientation events for the 40 transfer and exchange students 
matriculating to Duke. Maintained a community for the 
students throughout the year with occasional events to 
immerse them in student life at Duke. Developed personal 
relationships with 5 of the new students and facilitated their 
integration into Duke student life. 
5/13 – 6/13  Coach for College Coach 
Taught Physics and Life Skills and Coached Soccer to 150 
Vietnamese 7th and 8th grade students in impoverished rural 
Vietnam. Worked as a team of 8 American college student 
athletes and 8 Vietnamese college students to plan, revise, 
and implement lesson plans in Physics, Math, Biological 
Sciences, English, Soccer, Basketball, Volleyball, and 
Baseball. Integrated the lessons to help the students to 
develop excitement for and proficiency in science, 
leadership, language, and life skills using sports as a means 
to applied learning. 
 
Languages 
Professional proficiency in Spanish. 
 
 
